De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection

International Urology and Nephrology

Volumn 40, Issue 2, 2008, Pages 539-541

  Tovar, Jose L ^a   Buti, Maria ^a   Segarra, Alfonso ^a   Majó, Joaquim ^a   Esteban, Rafael ^a  

^a HOSPITAL GENERAL DE CATALUNYA   (Spain)

Author keywords

Interferon alfa 2b ribavirin combination therapy; Nephrotic syndrome; Renal toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; HEPATITIS C; HUMAN; MIDDLE AGED; NEPHROTIC SYNDROME;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; NEPHROTIC SYNDROME; RIBAVIRIN;

EID: 52649174253     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-007-9241-7     Document Type: Article

References (15)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Eng J Med 341:556-562
2. Kumar D, Wallington-Beddoe C, George J, Lin R, Samarasinhe D, Liddle C, Farrel G (2003) Effectiveness of interferon alfa 2b/ribavirin combination therapy for chronic hepatitis C in a clinical setting. Med J Aust 178:267-271
3. Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales FL et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982
4. Russo MW, Fried MW (2003) Side effects of therapy for chronic hepatitis C. Gastroenterology 124:1711-1719
5. Willson RA (2002) Nephrotoxicity of interferon alfaribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 35:89-92
6. Bruchfeld A, Lindahl K, Stale L, Söderberg M, Schvarcz R (2003) Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 18:1573-1580
7. Covic A, Maftei I-D, Mardare NGI et al (2006) Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodyalisis patients: results from a large, multicenter audit. J Nephrol 19:794-801
8. Gluud C, Gluud LL, Brok J (2006) Ribavirin monotherapy for chronic hepatitis C infection: a Chochrane hepato-biliary group systematic review and meta-analysis of randomised trials. Am J Gastroenrol 101:842-847
9. D'Amico G (1998) Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 54:650-671
10. Ohta S, Yokoyama H, Wada T et al (1999) Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection and interferon therapy. Am J Kidney Dis 33:1040-1048
11. Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal antiinflamatory drugs. N Engl J Med 310:663-572
12. Schlam SW, Hanson BE, Chemello L et al (1997) Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: meta-analysis of individual patient data from European centers. J Hepatol 26:961-966
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965
14. Izzedine H, Lanuay-Vacher V, Bourry E et al (2006) Druginduced glomerulopathies. Expert Opin Drug Saf 5:1-12
15. Brok J, Gluud LL, Gluud C (2005) Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomised trials. Arch Intern Med 165:2206-2212